Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

A BRCA2 Mutation, 4088insA, in a Finnish Breast and Ovarian Cancer Family Associated with Favourable Clinical Course

JAANA M. HARTIKAINEN, ARTO MANNERMAA, SEPPO HEINONEN, VELI-MATTI KOSMA and VESA KATAJA
Anticancer Research November 2007, 27 (6C) 4295-4300;
JAANA M. HARTIKAINEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jaana.hartikainen@uku.fi
ARTO MANNERMAA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SEPPO HEINONEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VELI-MATTI KOSMA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VESA KATAJA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Mutations in the BRCA1/2 genes confer a high risk for breast and ovarian cancer, with usually adverse clinical characteristics. The clinical course and response to treatment in mutation carriers have been reported infrequently and are assumed to be worse than in sporadic breast cancer. Patients and Methods: Eleven members of an Eastern Finnish family with multiple cases of breast and ovarian cancers were screened for BRCA1/2 mutations using protein truncation test (PTT), conformation-sensitive gel electrophoresis (CSGE) and sequencing. Results: Five of the six BRCA2 4088insA mutation carriers were affected. Mutation-positive breast/ovarian cancer patients had an excellent response to treatment even when prognosis as assessed by classical factors was poor. Conclusion: The 4088insA mutation appears to be associated with a favourable clinical course of breast and ovarian cancer, providing an informative example on the role of an individual mutation in assessing the prognosis for mutation carriers. Our results encourage more research on the effects of an individual mutation on clinical characteristics, response to treatment and outcome.

  • BRCA2
  • breast cancer
  • familial
  • germline
  • mutation
  • ovarian cancer

Footnotes

  • Received June 26, 2007.
  • Revision received September 5, 2007.
  • Accepted October 1, 2007.
  • Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 27 (6C)
Anticancer Research
Vol. 27, Issue 6C
November-December 2007
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A BRCA2 Mutation, 4088insA, in a Finnish Breast and Ovarian Cancer Family Associated with Favourable Clinical Course
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 16 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
A BRCA2 Mutation, 4088insA, in a Finnish Breast and Ovarian Cancer Family Associated with Favourable Clinical Course
JAANA M. HARTIKAINEN, ARTO MANNERMAA, SEPPO HEINONEN, VELI-MATTI KOSMA, VESA KATAJA
Anticancer Research Nov 2007, 27 (6C) 4295-4300;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
A BRCA2 Mutation, 4088insA, in a Finnish Breast and Ovarian Cancer Family Associated with Favourable Clinical Course
JAANA M. HARTIKAINEN, ARTO MANNERMAA, SEPPO HEINONEN, VELI-MATTI KOSMA, VESA KATAJA
Anticancer Research Nov 2007, 27 (6C) 4295-4300;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Tumor Budding Grade and T Stage as Recurrence Predictors of High-risk Stage II Colorectal Cancer
  • Pathologic Complete Response (pCR) in Patient With Myxofibrosarcoma Who Underwent Neoadjuvant Radiation Concurrent to Complementary and Alternative Medicine
  • Machine Learning Model to Guide Empirical Antimicrobial Therapy in Febrile Neutropenic Patients With Hematologic Malignancies
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire